126 related articles for article (PubMed ID: 37437018)
1. PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK.
Jiang TY; Cui XW; Zeng TM; Pan YF; Lin YK; Feng XF; Tan YX; Yuan ZG; Dong LW; Wang HY
Sci Transl Med; 2023 Jul; 15(704):eadd7464. PubMed ID: 37437018
[TBL] [Abstract][Full Text] [Related]
2. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Jiang TY; Pan YF; Wan ZH; Lin YK; Zhu B; Yuan ZG; Ma YH; Shi YY; Zeng TM; Dong LW; Tan YX; Wang HY
Sci Transl Med; 2020 Sep; 12(562):. PubMed ID: 32967970
[TBL] [Abstract][Full Text] [Related]
3. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
4. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
[TBL] [Abstract][Full Text] [Related]
5. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
6. PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis.
Jiang TY; Shi YY; Cui XW; Pan YF; Lin YK; Feng XF; Ding ZW; Yang C; Tan YX; Dong LW; Wang HY
Gastroenterology; 2023 Mar; 164(3):424-438. PubMed ID: 36436593
[TBL] [Abstract][Full Text] [Related]
7. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
8. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.
Lee D; Do IG; Choi K; Sung CO; Jang KT; Choi D; Heo JS; Choi SH; Kim J; Park JY; Cha HJ; Joh JW; Choi KY; Kim DS
Mod Pathol; 2012 Jan; 25(1):131-9. PubMed ID: 21874010
[TBL] [Abstract][Full Text] [Related]
9. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
16. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
17. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Janku F; Javle MM; Sen S; Pant S; Bramwell LG; Subbiah V; Way T; Wages DS; Wheeler CA; Suzuki T; Saeki K; Subach RA; Madden T; Maier G; Johansen MJ; Cheung K; Falchook GS
Cancer; 2023 May; 129(10):1537-1546. PubMed ID: 36882377
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 2A regulates deoxycytidine kinase activity via Ser-74 dephosphorylation.
Amsailale R; Beyaert M; Smal C; Janssens V; Van Den Neste E; Bontemps F
FEBS Lett; 2014 Mar; 588(5):727-32. PubMed ID: 24462681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
